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Immobilization fplasminogen via its lysine-binding sites is regarded as a prerequisite for its activation and function 
in fibrinolysis and pericellular p oteolysis. In the present study, the interaction of plasminogen with fimbriae found on 
Escherichia coli strains causing invasive human infections was studied. Plasminogen displayed concentration-dependent 
and saturable binding to immobilized type 1 fimbriae and, several fold lower binding to P and S fimbriae. The binding 
to fimbriae was effectively inhibited by e-aminocaproic acid indicating that it was mediated by the lysine-binding sites 
of plasminogen. Binding studies with mutated fimbriae and inhibition tests indicated that the interaction was not depen- 
dent on the lectin subunit of the fimbriae. These results indicate the existence ofa novel type of host-microbe interaction 
which may be important inthe invasion by bacteria of host issues. 
Plasminogen; Bacterial dhesin; (E. coli) 
1. INTRODUCTION 
The serine protease plasmin plays a central role 
in various physiological and pathological processes 
involving degradation of extracellular matrix pro- 
teins [1]. In addition to intravascular fibrinolysis 
[2], plasmin has been proposed to digest 
pericellular proteins in inf lammatory response 
[3-5], tumor cell invasion [6], ovulation and im- 
plantation [7], and neuronal development [8]. Ac- 
tivation of plasminogen by tissue plasminogen 
activator is kinetically unfavorable in the fluid 
phase but is remarkably promoted by immobiliza- 
tion of plasminogen via its lysine-binding sites 
[9-11]. Immobilization also protects the activated 
plasmin from tr2-antiplasmin, which in the fluid 
phase rapidly inactivates plasmin [11,12]. Further- 
more, the presence of specific receptors for 
plasminogen on endothelial cells [11] and inflam- 
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matory cells [4,5] is thought to be an important 
mechanism for generating localized proteolytic ac- 
tivity on the cell surface. 
Similarly to invasive animal cells, pathogenic 
bacteria must evidently also break down ex- 
tracellular matrix components in order to invade 
host tissues through basement membranes. The 
ability of streptokinase to activate plasminogen 
[13] and the presence of a plasmid-encoded 
plasminogen activator in Yersinia pestis [14] sug- 
gest that bacteria might utilize plasmin for this 
purpose. To investigate further this possibility, we 
have studied here the interaction of plasminogen 
with fimbriae found on Escherichia coli strains 
causing invasive infections. Fimbriae are protein 
filaments typically consisting of a major structural 
subunit and a few minor proteins including a lectin 
subunit which mediates bacterial attachment to 
host cells [15,16]. Recently, E. coli P fimbriae were 
found to bind to fibronectin via a mechanism that 
does not involve the lectin subunit [17], suggesting 
that bacterial fimbriae are multifunctional proteins 
with lectin-dependent and -independent functions. 
We report here that plasminogen binds via its 
lysine-binding sites to type 1 fimbriae that com- 
monly occur in E. coli strains, including those 
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causing invasive human infections [15]. Specific 
b inding of plasminogen was also observed to P 
f imbriae which are closely associated with 
pyelonephritogenic strains and S f imbriae that oc- 
cur in strains causing septic neonatal  infections 
[18,19]. 
2. MATERIALS  AND METHODS 
2.1. Materials 
Human Glu-plasminogen and plasmin were from 
KabiVitrum (Stockholm). Rabbit polyclonal plasminogen- 
specific IgG was obtained from Dakopatts (Clostrup, Den- 
mark). Labeling of IgG with europium chelate (isothio- 
cyanatophenyldiethylenetriaminepentaacetic acid complexed 
with europium; Wailac, Turku, Finland) was carried out essen- 
tially as described [20]. e-Aminocaproic a id (EACA) and ol- 
methyl mannoside were obtained from Sigma (St. Louis, MO). 
Laminin was from Bethesda Research Labs (Gaithersburg, 
MD). 
2.2. Bacterial fimbriae 
Fimbriae were purified by using deoxycholate and concen- 
trated urea [21] from E. coli strains that carry recombinant 
plasmids encoding type 1 fimbriae (EH827) [22], P fimbriae 
(pPILI10-75), mutated P fimbriae lacking lectin activity 
(pPILlI0-7501) [23], and S fimbriae (HB101(pANN801-4)) 
[24]. Yeast cell agglutination tests with type-l-fimbriated 
bacteria were carried out as in [25]. 
2.3. Binding assay 
The proteins tudied were allowed to attach to polystyrene 
microtitration strip wells (Titertek, Labsystems, Helsinki, 
Finland) in 100/el PBS (10/zg/ml) overnight at 4°C. The wells 
were washed twice with washing solution [0.15 M NaCl con- 
taining 0.05070 (v/v) Tween 20] and incubated with PBS (10 mM 
phosphate buffer, pH 7.4, 150 mM NaCI) containing 1mg/ml 
BSA for 3 h at room temperature. The wells were washed twice, 
plasminogen was added in 100/~l PBS containing 0.05070 Tween 
20, and incubation performed for 2 h at room temperature with 
continuous shaking. The wells were washed three times, 100/d 
europium-labeled plasminogen-specific IgG was added (about 
50 ng IgG/well) in 50 mM Tris buffer, pH 7.8, containing 
150 mM NaC1, 5 mg/ml BSA, 1 mg/ml bovine globulin, and 
5 mM NAN3, followed by incubation for 1 h at room 
temperature with continuous shaking. The wells were washed 
four times, 200/A Enhancement solution (Wailac) [20] was add- 
ed and fluorescence was measured after 20 min in an Arcus 
Fluorometer (WaUac). The coefficient of variation for duplicate 
wells was 4.8070 on average. Antibody controls, i.e. wells 
without any plasminogen added but otherwise processed as 
described above, gave insignificant fluorescence values (less 
than 2000 cps) with all immobilized proteins. 
3. RESULTS 
Plasminogen bound in a concentration- 
dependent manner  to all three immobil ized tim- 
briae studied (fig.l). Binding to type 1 f imbriae 
was about 4-6-t imes higher than that to S or P 
f imbriae. Under the test conditions used, 
plasminogen bound to immobil ized laminin, a 
formerly characterized target of plasminogen [26], 
to the same extent as to type 1 f imbriae whereas no 
binding to BSA (fig. 1) and transferrin (not shown) 
was observed. The binding to type 1 fimbriae 
became saturated at plasminogen concentrat ion of
20-30/zg /ml  indicating an apparent Kd value of 
0.1 -0 .2 /zM.  Binding to P and S f imbriae was less 
clearly saturable (fig. 1). 
Binding of plasminogen to the bacterial f imbriae 
was effectively inhibited by the lysine analog 
EACA (fig.2). The binding to type 1 f imbriae was 
most completely inhibited, i.e. by over 90°70 in the 
presence of 20 mM EACA.  At the same inhibitor 
concentrat ion, the binding to P and S f imbriae was 
decreased by about 70 and 50070, respectively. 
To assess the involvement of the formerly 
characterized lectin-activity of the f imbriae in the 
interaction with plasminogen, binding of 
plasminogen to mutated P fimbriae lacking the lec- 
tin subunit  was compared to binding to wild-type 
P fimbriae. No difference was observed (fig.3). 
Furthermore,  binding of plasminogen to type 1 
f imbriae was not affected in the presence of 
50 mM methyl cr-mannoside (not shown), a sugar 
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Fig.1. Interaction of plasminogen with immobilized E. coil 
fimbriae. Plasminogen was incubated for 2 h at room 
temperature in microtiter wells coated with type 1 fimbriae 
(o), P fimbriae (e), S fimhriae (a), laminin (A) or BSA (n). 
After washing, the wells were incubated with a europium- 
labeled plasminogen-specific antibody and measured for time- 
resolved fluorescence. Each point represents he mean of 
duplicate wells. 
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Fig.2. Effect of EACA on plasminogen binding to immobilized 
fimbriae. Plasminogen was incubated with ( - - - )  and without 
( ) 20 mM EACA in microtiter wells coated with type l 
fimbriae (o), P fimbriae (o), S fimbriae (zx) or BSA (n). 
Bound plasminogen was determined by a europium-labeled 
antibody. Note the different scale of the y-axis in A and B. 
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Fig.3. Interaction fplasminogen with intact and mutated P 
fimbriae. Plasminogen was incubated in microtiter wells coated 
with P fimbriae (o), mutated P fimbriae lacking the lectin 
subunit (o) or BSA (tn). Bound plasminogen was determined 
by a europium-labeled antibody. 
that totally inhibits the binding of type 1 fimbriae 
to eukaryotic ells and glycoproteins [15], and 
yeast cell agglutination by type I fimbriae was not 
inhibited by plasminogen at 100/~g/ml (not 
shown). On the other hand, treatment of 
type-l-fimbriated bacteria with activated plasmin 
(100/zg/ml for 2 h at 37°C) did not influence their 
ability to agglutinate yeast cells (not shown). 
4. DISCUSSION 
The present study provides the first evidence on 
the interaction of plasminogen with surface com- 
ponents of pathogenic bacteria. Our results 
demonstrate hat plasminogen binds to the fim- 
brial types most commonly found in E. coli strains 
causing pyelonephritis, urosepsis, and neonatal 
meningitis. The inhibition with EACA [27] in- 
dicated that the binding to type 1 fimbriae was 
almost otally mediated by the lysine-binding sites 
of plasminogen. The binding of plasminogen to S 
and P fimbriae was also predominantly sine 
binding site-mediated, as indicated by the 50-70% 
inhibition caused by EACA. 
Immobilization of plasminogen via the lysine- 
binding sites critically enhances its activation by 
tissue plasminogen activator and protects plasmin 
from inactivation by the primary plasmin in- 
hibitor, cr2-antiplasmin [9-12]. Binding of 
plasminogen to bacterial fimbriae may thus 
generate localized plasmin activity on the bacterial 
surface. Since plasmin effectively digests different 
extracellular matrix proteins [28,29] and activates 
collagenase [30], bacterium-bound plasmin may 
provide an effective means for bacteria to invade 
host tissues. On the other hand, the present finding 
that plasmin treatment of type 1 fimbriae did not 
influence their ability to agglutinate y ast ceils sug- 
gests that fimbriae themselves are not digested by 
plasmin. This is in agreement with earlier observa- 
tions on the resistance of fimbrial filaments to pro- 
teases including trypsin [31]. 
Several lines of evidence suggest that 
plasminogen binding is not related to the formerly 
characterized cell-binding activities of the bacterial 
fimbriae that are specific for carbohydrate struc- 
tures [15]. First, mutated P fimbriae lacking the 
lectin subunit bound plasminogen to an extent 
similar to that of wild-type P fimbriae. Second, the 
receptor analog saccharide of type 1 fimbriae, 
methyl cr-mannoside, did not inhibit their 
plasminogen-binding activity, and third, 
plasminogen did not inhibit the binding of type 1 
fimbriae to yeast cells. Plasminogen binding thus 
represents a novel property in bacterial fimbriae 
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and is a further indication of their multifunctional 
nature. Our results suggest hat the pathogenic 
function of fimbriae is not limited to bacterial 
adhesion to mucosal surfaces of the host but that 
fimbriae may also play a part in septicemia. This 
proposal is also supported by recent evidence in- 
dicating that S fimbriae bind to vascular en- 
dothelium and choroid plexus [32]. 
Plasminogen binding to E. coli fimbriae in- 
dicates the existence of a novel type of host- 
microbe interaction in bacterial infections. Type 1 
fimbriae are commonly found and have a similar 
structure in most enterobacterial genera [15]; it can 
therefore be expected that the binding activity 
described here occurs in bacteria other than E. 
coli. 
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